ArticleJournal of clinical microbiology2015
Continuing Challenges for the Clinical Laboratory for Detection of Carbapenem-Resistant Enterobacteriaceae.
Article in Journal of clinical microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Evaluating the Performance of Two Rapid Immunochromatographic Techniques for Detecting Carbapenemase in Carbapenem-ResistantInfection and drug resistance · 2025Article
- A Rapid Carbapenemase Genes Detection Method with Xpert Carba-R from Positive Blood Cultures Compared with NG-Test Carba 5 and Sequencing.Infection and drug resistance · 2022Article
- Routine detection of carbapenem-resistant gram-negative bacilli in clinical laboratories. A review of current challenge.Saudi medical journal · 2018Review
- PCR-Dipstick Chromatography for Differential Detection of Carbapenemase Genes Directly in Stool Specimens.Antimicrobial agents and chemotherapy · 2017Article
- Use of Ancillary Carbapenemase Tests To Improve Specificity of Phenotypic Definitions for Carbapenemase-Producing Enterobacteriaceae.Journal of clinical microbiology · 2017Article
- Development of selective medium for IMP-type carbapenemase-producing Enterobacteriaceae in stool specimens.BMC infectious diseases · 2017Article
- Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-BorneAntimicrobial agents and chemotherapy · 2017Article
- Impact of Delays between Clinical and Laboratory Standards Institute and Food and Drug Administration Revisions of Interpretive Criteria for Carbapenem-Resistant Enterobacteriaceae.Journal of clinical microbiology · 2016Article
Corrections and comments
- Comment on
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Detecting carbapenem-resistant Enterobacteriaceae (CRE) can be difficult. In particular, the absence of FDA-cleared automated antimicrobial susceptibility test (AST) devices that use revised Clinical and Laboratory Standards Institute (CLSI) carbapenem breakpoints for Enterobacteriaceae and the lack of active surveillance tests hamper the clinical laboratory. In this issue of the Journal of Clinical Microbiology, Lau and colleagues (A. F. Lau, G. A. Fahle, M. A. Kemp, A. N. Jassem, J. P. Dekker, and K. M. Frank, J Clin Microbiol 53:3729-3737, 2015, http://dx.doi.org/10.1128/JCM.01921-15) evaluate the performance of a research-use-only PCR for the detection of CRE in rectal surveillance specimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.